Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Bristol-Myers Squibb (BMS)

Status

Enrolling

Conditions

Psoriasis

Treatments

Drug: Deucravacitinib

Study type

Observational

Funder types

Industry

Identifiers

NCT07256015

IM011-1228

Details and patient eligibility

About

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
Patients have moderate to severe plaque psoriasis
Patients have signed informed consent form (ICF)

Exclusion criteria

Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF